Anupam Dalal
CIK 1602474 · last filed 2026-07-30
Anupam Dalal is a corporate insider who has filed 18 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing shows the insider was granted $5.0M of WHWK on Jul 30, 2026. Across all open-market trades the lifetime net is +$40.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $14.7M across reported positions. 2 SEC filings were submitted jointly with Caley Castelein.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AADI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN FRANCISCO, CA 94108
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WHWK | Director | 4,687,042 | $3.13 | $14.67M | $0 | 2 | 2026-07-30 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | 3,411,532 | $2.05 | $6.99M | $40.00M | 7 | 2025-03-05 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Director | 1,131 | $33.00 | $37.3K | $0 | 5 | 2021-07-02 |
| AKBA | Director | — | $0.42 | — | $0 | 2 | 2016-06-20 |
| Neos Therapeutics, Inc. (NEOS) Delisted | 10%+ Owner | 1,215,052 | $1.15 | $1.40M | $0 | 1 | 2015-07-28 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| WHWK | Direct | 1,130 | 0.0% | 2026-07-30 |
| See footnote | 4,685,912 | 100.0% | 2026-07-30 | |
| Total | 4,687,042 | |||
| AADI | Direct | 1,130 | 0.0% | 2025-03-05 |
| See footnote | 3,410,402 | 100.0% | 2025-03-05 | |
| Total | 3,411,532 | |||
| NEOS | Burrill Life Sciences Capital Fund III, L.P. See Footnote |
1,215,052 | 100.0% | 2015-07-28 |
| Total | 1,215,052 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-30 | WHWK | Grant (A) | +1,275,510 | $5.00M | EDGAR |
| 2025-06-16 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2025-03-05 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | +1,561,000 | $3.75M | EDGAR |
| 2024-06-14 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-09-27 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | +320,000 | $4.00M | EDGAR |
| 2022-06-17 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-31 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Buy (P) | +1,529,402 | $20.00M | EDGAR |
| 2021-08-30 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Mixed | +1,529,402 | $20.00M | EDGAR |
| 2021-07-02 | Whitehawk Therapeutics, Inc. (ARPO) Delisted | Grant (A) | +7,400 | $11.2K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).